Compare Enveric Biosciences Inc (ENVB) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lowe`s Companies Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Lowe`s Companies Inc trades at $185.52 (market cap $105.96B). The key difference: Lowe`s Companies Inc is far larger — about 15582.4× Enveric Biosciences Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Lowe`s Companies Inc for 98 Days on average.
| ENVB | LOW | |
|---|---|---|
Market Cap | $6.80M | $105.96B |
Volume | 64,867 | 4,039,547 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $287.39 |
52-Week Low | $1.27 | $179.50 |
Typical Hold Time | 14 Days | 98 Days |
Enterprise Value | -$1.49M | $144.81B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Lowe's (LOW) trades at $185.27, up 2.05% today, but faces a bearish technical signal with key resistance at $191. The company reported Q2 2026 EPS of $4.40, beating estimates, yet revenue has declined from $96.2B in 2022 to $83.7B in 2025. Analysts maintain a strong buy consensus with a $244.09 price target, citing value despite industry headwinds. Recent news highlights drone delivery innovation with DoorDash and Alphabet's Wing, aiming to enhance customer convenience.
LOW presents a value opportunity with a P/E of 15.96 and bullish analyst sentiment, but risks include a challenging housing market and declining revenue trends. The stock's upside hinges on execution of new initiatives and economic recovery in home improvement spending, with near-term volatility expected amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
